Riskpilot← Back to searchSign inGet full accessRevvity Omics Sweden AB
ABActiveOrg 5590410717Vetenskapsvägen 10Technical testing and analysis · NACE 7120Est. 20153 employees
Revenue 2024
SEK 7,9M
+817% vs 2023
EBITDA margin
-2.9%
+97% vs 2023
Equity ratio
3.8%
Financial strength
Net profit 2024
SEK -118,3M
+74% vs 2023
| Revenue | SEK 7,9M | +817% |
| EBITDA | SEK -231K | +97% |
| Net profit | SEK -118,3M | +74% |
| Total assets | SEK 50,7M | -81% |
| Equity | SEK 1,9M | -98% |
| Employees | 3 | — |
Legal name
Revvity Omics Sweden AB
Org number
5590410717
Legal form
Aktiebolag
NACE code
7120 · Technical testing and analysis
Founded
14 december 2015
Share capital
SEK 50 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna externa firmatecknarna
Company purpose
Bolaget ska bedriva laboratorietester för kunders räkning samt därmed förenlig verksamhet.
Address
Vetenskapsvägen 10
Email
cc.nordic@perkinelmer.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2 122 | 858 | 7 872 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −8 995 | −2 753 | −5 804 | −8 808 | −231 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −8 995 | −2 753 | −5 804 | −8 808 | −231 |
| Net financials | 3 446 | 1 586 | −458 | −447 950 | −118 035 |
| Profit before tax | 491 | 10 214 | −2 762 | −456 758 | −118 266 |
| Tax | −0 | −387 | −0 | −0 | −0 |
| Net profit | 491 | 9 827 | −2 762 | −456 758 | −118 266 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 899 436 | 267 538 | 225 596 | 268 676 | 50 662 |
| Equity | 113 881 | 123 708 | 120 946 | 81 188 | 1 939 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 785 555 | 143 830 | 104 650 | 187 488 | 48 723 |
| Total debt | 785 555 | 143 830 | 104 650 | 187 488 | 48 723 |
EBITDA margin
-2.9%
This company
15.8%
Market median
-118% vs market
20202024
Equity ratio
3.8%
This company
38.2%
Market median
-90% vs market
20202024
Return on equity
-6099.3%
This company
18.4%
Market median
-33248% vs market
20202024
Net profit margin
-1502.4%
This company
8.1%
Market median
-18648% vs market
20202024
Asset turnover
0.16×
This company
1.12×
Market median
-86% vs market
20202024
Debt / equity
25.13×
This company
0.62×
Market median
-3953% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
RN Chief Auditor | Chief Auditor | 2022 |
ÅA External Signatory | External Signatory | 2025 |
BF External Signatory | External Signatory | 2024 |
| Former (2) | ||
LO Authorized Recipient of Service | Authorized Recipient of Service | 2022 – 2024 |
AC Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2025 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2026 | |
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
REVVITY HOLDING LUXEMBOURG SRL
Revvity Omics Sweden AB Board members of Revvity Omics Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Nicklas Kullberg | Chief Auditor | 0 companies |
| Lars Olof Henrik Andersson | Authorized Recipient of Service | 0 companies |
| Antonio Castillo Espinosa | Chief Executive Officer | 0 companies |
| Åsa Anna Maria Janfalk Carlsson | External Signatory | 0 companies |
| Bo Fredrik Gabriel Åhbeck | External Signatory | 0 companies |
| Malak Benyakhlef | Board of Directors | 0 companies |
| Mark William March | Chairman | 0 companies |
| John Leo Healy | Board of Directors | 0 companies |
| Massimo Maggioni | Board of Directors | 0 companies |